Related Experiment Video
Updated: Jun 27, 2026

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
Published on: November 30, 2022
The epidemiology of NSAID gastropathy: the ARAMIS experience
1ARAMIS Program, Stanford University School of Medicine, Palo Alto, California 94304-1808, USA.
Abstract:
The Arthritis, Rheumatism, and Aging Medical Information System (ARAMIS) is a national database for longitudinal outcome information obtained form the long-term follow-up of patients with rheumatic disease. This database has been used to investigate the parameters associated with nonsteroidal anti-inflammatory drug (NSAID) gastropathy in a population of 2747 patients with rheumatoid arthritis (RA). Theses patients were found to have a 1.3% higher risk of hospitalization each year because of a gastrointestinal (GI) adverse event than the general population. In these patients with RA, there was a five fold higher risk of hospitalization and a twofold increase in GI mortality among NSAID users compared with the general population. Age was the most significant predictor of serious GI events in our study' disability, prednisone therapy, and previous NSAID-related GI events were also identified as risk factors. An objective index of drug toxicity was developed to facilitate comparisons of the potential risks involved with specific drug regimens. consistent toxicity scores were obtained for NSAIDs, with threefold to fourfold difference between drugs having low risk versus high risk. These studies indicate a need for changes in management practices in at-risk patients and a potential role for better tolerated NSAIDs, such as the recently developed cyclooxygenase-2 selective or preferential drugs.
Related Concept Videos
Peptic Ulcer Disease III: Clinical Manifestations and Complications
Assessment of the Gastrointestinal System I: Subjective Data
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems related to...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Peptic Ulcer Disease II: Pathophysiology
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
